help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Palmer, G.
Right arrow Articles by Caverzasio, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palmer, G.
Right arrow Articles by Caverzasio, J.
Endocrinology Vol. 138, No. 12 5202-5209
Copyright © 1997 by The Endocrine Society


ARTICLES

Expression of a Newly Identified Phosphate Transporter/Retrovirus Receptor in Human SaOS-2 Osteoblast-Like Cells and Its Regulation by Insulin-Like Growth Factor I1

Gaby Palmer, Jean-Philippe Bonjour and Joseph Caverzasio

Division of Bone Diseases, Department of Medicine, University of Geneva, Geneva, Switzerland

Address all correspondence and requests for reprints to: Dr. Joseph Caverzasio, Division of Bone Diseases, Department of Medicine, University of Geneva, CH-1211 Geneva 14, Switzerland. E-mail: caverzas{at}cmu.unige.ch


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The cell surface receptor for gibbon ape leukemia virus (Glvr-1) was recently demonstrated to serve normal cellular functions as a sodium-dependent phosphate (NaPi) transporter. This protein belongs to a newly identified phosphate transporter/retrovirus receptor gene family distinct from renal type I and II NaPi transporters. Although inorganic phosphate (Pi) transport is an important function of osteoblasts and of the matrix vesicles produced by these cells in the context of bone matrix calcification, the molecular identity of the NaPi transport system(s) present in this cell type is still unknown. In contrast to Pi uptake mediated by renal NaPi transporters, the activities of both the osteoblastic transport system and Glvr-1 are decreased at alkaline pH, and this observation led us to investigate expression of this transporter in human SaOS-2 osteosarcoma cells.

Northern blotting analysis revealed the presence of a 4-kilobase Glvr-1 transcript. The expression of Glvr-1 messenger RNA (mRNA) was increased in response to insulin-like growth factor I (IGF-I). Associated with this effect, a selective, dose- and time-dependent stimulation of NaPi transport was observed. Actinomycin D and cycloheximide abolished the increase in NaPi transport, which thus appeared to be dependent on RNA and protein synthesis. The increase in Glvr-1 mRNA induced by IGF-I was dose dependent and transient, peaking after 4 h (~4-fold increase in response to 10-7 M IGF-I). It preceded the maximal expression of NaPi transport stimulation (173–235% of control), which was observed after 18–24 h. Induction of Glvr-1 mRNA expression by IGF-I was inhibited by actinomycin D, suggesting that this effect was related to an increase in gene transcription. The stability of Glvr-1 mRNA was not altered by IGF-I, and Glvr-1 mRNA induction did not require the synthesis of new proteins.

These data demonstrate for the first time regulated expression of mRNA encoding the type III NaPi transporter Glvr-1 in osteoblast-like cells. They also suggest that this new transporter family may be involved in Pi handling in osteogenic cells and in its regulation by osteotropic factors.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
INORGANIC phosphate (Pi) is essential for the formation and mineralization of bone. Pi is indeed not only an integral component of the hydroxyapatite crystal, but is also necessary for the development and the activity of osteogenic cells, which are involved in the synthesis and calcification of the bone extracellular matrix.

Pi uptake in osteoblast-like cells is a saturable, carrier-mediated process that can be regulated by many osteotropic factors, including PTH, platelet-derived growth factor, and fluoride (1, 2). Pi enters the cells through a sodium-dependent Pi (NaPi) transport system present in the plasma membrane (1, 2, 3). A Pi carrier with similar functional properties is also found in the matrix vesicles released by osteogenic cells into the bone extracellular matrix, where accumulation of Pi is thought to play an essential role in the initiation of matrix calcification (1, 2). Although substantial information is available about the functional characteristics of this transport system, its molecular identity is unknown.

During the last years, several mammalian NaPi transporter families have been described (4, 5, 6, 7). Two nonhomologous sodium-phosphate cotransport systems, called type I and II NaPi, were identified in the renal cortex of various species (4). Both types of transporters are almost exclusively expressed in the kidney, where, in particular, type II NaPi plays a major role in the regulation of proximal tubular phosphate transport (4). More recently, the cell surface receptors for gibbon ape leukemia virus (Glvr-1) and amphotropic murine retrovirus (Ram-1) have been demonstrated to serve normal cellular functions as sodium-dependent phosphate transporters (5, 6, 7). These proteins belong to a new type III phosphate transporter/retrovirus receptor gene family and are expressed in a wide variety of tissues (5, 7).

The three types of NaPi differ markedly in tissue distribution, structure, and function (4, 7). Characteristics of Pi transport in bone-forming cells suggest that involved carriers are distinct from the type I and II renal transporters (3, 4). Recent studies showed that injection of messenger RNA (mRNA) from rat osteoblast-like cells could induce NaPi transport in Xenopus laevis oocytes. This mRNA did not hybridize to rat renal NaPi-2, suggesting the presence in osteoblast-like cells of a transport system different from that of type II NaPi (8). A distinctive feature of the different types of NaPi is the influence of pH on their activity. Unlike the activity of renal NaPi transporters, which is increased at alkaline pH, Pi uptake mediated by type III NaPi is decreased when pH increases (4, 5, 6, 7). The osteoblastic Pi transport system exhibits a pH dependence similar to that of the type III NaPi (3), and this similarity prompted us to investigate whether type III family members were expressed in osteoblast-like cells.

Insulin-like growth factor I (IGF-I), which is an important regulator of Pi handling in the kidney, in particular during growth, is also one of the most abundant growth factors present in bone (9, 10, 11). As IGF-I has been demonstrated in various in vitro models to stimulate proliferation, differentiation, and Pi transport in osteogenic cells, we were further interested in the potential effect of IGF-I on our experimental system (10, 11, 12, 13).

The aims of this study were thus to investigate the expression of the type III NaPi Glvr-1 in human SaOS-2 cells, an osteosarcoma-derived cell line with many osteoblast-like characteristics, and to test whether expression of Glvr-1 and Pi uptake could be influenced by IGF-I in these cells.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Materials
FCS was obtained from Amimed Produkte-BioConcept (Allschwil, Switzerland), and all other cell culture reagents were purchased from Life Technologies (Basel, Switzerland). Recombinant human IGF-I was provided by Ciba Geigy (Basel, Switzerland) and was dissolved as a concentrated solution in a 0.1-M acetic acid solution containing 0.1 g/100 ml BSA. Actinomycin D and cycloheximide were obtained from Sigma Chemical Co. (St. Louis, MO) and dissolved as concentrated solutions in dimethylsulfoxide (DMSO). The RNeasy total RNA purification kit was obtained from Qiagen (Hilden, Germany). The 18S ribosomal RNA (rRNA) antisense oligonucleotide was obtained from MWG-Biotech (Ebersberg, Germany). Radiolabeled H3[32P]O4 and GeneScreen Plus membranes were purchased from DuPont de Nemours (Brussels, Belgium). Hybond N membranes, random nonamer-primed DNA labeling kit, [{alpha}-32P]deoxy-CTP, [{gamma}-32P]ATP, and [3H]alanine were obtained from Amersham International (Little Chalfont, UK). Immobilon S membranes were purchased from Millipore Corp. (Bedford, MA), and Zeta-Probe GT membranes were obtained from Bio-Rad Laboratories (Richmond, CA). Quickhyb hybridization buffer was obtained from Stratagene (La Jolla, CA). All other reagents were of the highest purity available from standard laboratory suppliers.

Autoradiographies were quantitated using the 300A Computing densitometer from Molecular Dynamics (Sunnyvale, CA).

Cell culture
Human osteoblast-like SaOS-2 cells (14) were cultured in DMEM-Ham’s F-12 (1:1) containing 10% FCS, 100 IU/ml penicillin, and 100 µg/ml streptomycin. All cultures were maintained at 37 C in a humidified atmosphere of 5% CO2-95% air. Subcultures were obtained once a week by removing the cells from the dishes using 0.25% trypsin in a Ca- and Mg-free Earle’s salt solution containing 2 mmol/liter EDTA. The cells were plated in 16-mm 24-well tissue culture clusters for Pi and alanine uptake measurements and DNA content determinations or in 162-cm2 cell culture flasks for RNA extraction. They reached confluence within 3 days, and the assays were performed on days 5–6. For all experiments, confluent SaOS-2 cells were preincubated for 18 h in DMEM-Ham’s F-12 medium containing 0.25% FCS before stimulation with IGF-I or its vehicle for the indicated times. In some experiments cells were exposed to 1 or 2 µg/ml actinomycin D before or after stimulation with IGF-I. Actinomycin D (1 µg/ml) has been previously shown to inhibit transcription in SaOS-2 cells (15). To inhibit translation, cells were preincubated for 90 min with 5 µM cycloheximide, a concentration sufficient to inhibit protein synthesis in SaOS-2 cells (16).

Uptake of Pi or alanine
Transport studies were performed in Earle’s Buffered Salt Solution (EBSS) as previously described (17). Pi transport was initiated by adding 0.3 ml EBSS containing 0.1 g/100 ml BSA, 0.1 g/100 ml D-glucose, and 0.1 mM H3[32P]O4 (1 µCi/ml), except for kinetic analyses, where H3[32P]O4 concentrations ranged from 0.05–1.5 mM. For alanine transport, the EBSS solution contained 0.1 mM L-[3H]alanine (1 µCi/ml) and 1 mM Na2HPO4. IGF-I, actinomycin D, cycloheximide, or their respective vehicles were not added to the uptake solution during the transport determination. After 6 min for Pi or 2 min for alanine, solute uptake was stopped by washing the cell layer three times with ice-cold (4 C) substrate-free EBSS. The cells were then solubilized with 300 µl 0.2 N sodium hydroxide, and the radioactivity was counted by a standard liquid scintillation technique. The sodium-independent components of Pi and alanine uptake were determined by replacing NaCl in the uptake solution with choline chloride.

DNA content
DNA content was measured in parallel to Pi and alanine uptake in cells that were stimulated with IGF-I or its vehicle for the indicated times. The cells were detached from the wells by a 10-min incubation at 37 C with 0.1% collagenase and 0.25% trypsin in Ca- and Mg-free Earle’s salt solution containing 2 mmol/liter EDTA, and DNA content was measured as described by Burton (18), using calf thymus DNA as a standard.

Northern blot analysis
After stimulation of SaOS-2 cells with IGF-I or its vehicle for the indicated times, the culture medium was removed, and the cells were stored at -80 C until total RNA was isolated using the RNeasy kit from Qiagen according to the manufacturer’s instructions. Ten micrograms of total RNA were denatured in glyoxal and separated by electrophoresis on a 1.2% agarose gel. RNA was transferred to Hybond N, GeneScreen Plus, Zeta-Probe GT, or Immobilon S membranes by capillary transfer. Membranes were UV cross-linked and stained with methylene blue to control equal sample loading.

The membranes were hybridized to a PCR-amplified fragment (from bp 1208 to bp 1920) of the human Glvr-1 complementary DNA (cDNA; GenBank accession no. L20859) (19), which was labeled with 50 µCi [{alpha}-32P]deoxy-CTP by random priming. This central region of the Glvr-1 cDNA exhibits low homology to the related Glvr-2 (GenBank accession no. L20852) (20). Prehybridization (30 min) and hybridization (2 h) were performed in Quickhyb buffer (Stratagene), which was supplemented for the hybridization with 100 µg/ml salmon sperm DNA. Membranes were washed twice for 15 min each time in 2 x SSC (standard saline citrate)-0.1% SDS at 25 C and for 10–30 min at 60 C in 0.1 x SSC-0.1% SDS before exposition to Kodak X-Omat AR films (Eastman Kodak, Rochester, NY) for 18–72 h at -80 C. To correct for differences in sample loading by assessing the expression of a housekeeping gene, membranes were stripped in 0.1 x SSC-0.1% SDS at 95 C and rehybridized with a BamHI fragment of the human cyclophilin cDNA (21), using hybridization conditions similar to those used for Glvr-1. Alternatively, equal sample loading was confirmed by rehybridizing the membranes to a 5'-end-labeled 32-mer oligonucleotide complementary to the human 18S rRNA (5'-CCTGTATTGTTATTTTTCGTCACTACCTCCCC-3'). Hybridization was carried out at 63 C in Quickhyb buffer supplemented with 100 µg/ml salmon sperm DNA. Membranes were washed for 5 min in 2 x SSC-0.5% SDS at 25 C, for 15 min in 2 x SSC-0.1% SDS at 25 C, and for 20 min in 0.1 x SSC-0.5% SDS at 37 C. Signals were quantitated by densitometry.

Statistical analysis
Results are expressed as the mean ± SEM. Significance of differences was calculated by two-tailed unpaired Student’s t test. A difference between experimental groups was considered significant when p < 0.05.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Characteristics of Pi transport stimulation by IGF-I in SaOS-2 cells
The effect of IGF-I on sodium-dependent Pi uptake was investigated in confluent SaOS-2 cells. The initial rate of Pi uptake was significantly increased in cells stimulated for 6 or 24 h with 10-7 M IGF-I (Table 1Go). The Na-independent component of Pi uptake accounted for less than 20% of total Pi uptake in vehicle-treated cells and was not affected by IGF-I. This component was thus neglected in further experiments. Sodium-dependent Pi uptake was preferentially increased compared with sodium-dependent alanine transport, which was not changed after 6-h incubation with 10-7 M IGF-I and was only slightly increased after 24 h (Table 1Go). This observation suggests that the change in Pi uptake induced by IGF-I is mediated by a selective cellular mechanism rather than by a general alteration in the Na gradient driving force. In the same experimental conditions, DNA content was not changed in IGF-I-treated cells after 6 h and increased by only 15% after 24 h (Table 1Go).


View this table:
[in this window]
[in a new window]
 
Table 1. Selectivity of Pi transport stimulation by IGF-I in SaOS-2 cells

 
The stimulation of Pi transport by IGF-I was dose dependent (Fig. 1AGo). A significant increase was observed in response to 10-11 M IGF-I, and maximal stimulation was achieved at 10-8–10-7 M. The effect of IGF-I was time dependent and progressive; it was first detectable after 4 h and reached a maximal value after 18 h (Fig. 1BGo). Furthermore, the stimulation of Pi transport by IGF-I appeared to be dependent on RNA and protein synthesis, as it was completely blocked in cells pretreated with either actinomycin D (Fig. 2AGo) or cycloheximide (Fig. 2BGo). Kinetic analysis indicated that the stimulatory effect of IGF-I on Pi uptake was related to an increase in the maximal rate (Vmax) of the transport system, without a significant change in the apparent Km (Fig. 3Go and Table 2Go).



View larger version (11K):
[in this window]
[in a new window]
 
Figure 1. Dose- and time-dependent effect of IGF-I on Pi transport in SaOS-2 cells. A, Confluent SaOS-2 cells were stimulated with various concentrations of IGF-I or with its vehicle for 24 h before determination of Pi uptake. Each symbol represents the mean ± SEM of five or six determinations in a representative experiment. *, P < 0.05; **, P < 0.001 (compared with vehicle-treated cells). B, Confluent SaOS-2 cells were stimulated with 10-7 M IGF-I or its vehicle for the indicated times before determination of Pi uptake. Values for IGF-I-treated cells are expressed as percentages compared with those for vehicle-treated cells at the same time point. Each symbol represents the mean ± SEM of five or six determinations in a representative experiment. *, P < 0.01; **, P < 0.001 (compared with vehicle treated cells at the same time point).

 


View larger version (10K):
[in this window]
[in a new window]
 
Figure 2. Effect of actinomycin D and cycloheximide on Pi transport stimulation by IGF-I in SaOS-2 cells. A, Confluent SaOS-2 cells were preincubated with 1 µg/ml actinomycin D or with its solvent (DMSO; final concentration in the culture medium, 0.02%) for 2 h. The cells were then stimulated with 10-7 M IGF-I (black columns) or its vehicle (white columns) in the presence of the inhibitor or DMSO for 24 h before determination of Pi uptake. Each column represents the mean ± SEM of six determinations in a representative experiment. *, P < 0.001 compared with DMSO- and vehicle-treated cells. B, Confluent SaOS-2 cells were preincubated with 5 µM cycloheximide or its solvent (DMSO; final concentration in the culture medium, 0.05%) for 90 min. The cells were then stimulated with 10-7 M IGF-I (black columns) or its vehicle (white columns) in the presence of the inhibitor or DMSO for 24 h before determination of Pi uptake. Each column represents the mean ± SEM of six determinations in a representative experiment. *, P < 0.001 compared with DMSO- and vehicle-treated cells.

 


View larger version (14K):
[in this window]
[in a new window]
 
Figure 3. Kinetic analysis of Pi transport stimulation by IGF-I in SaOS-2 cells. Confluent SaOS-2 cells were stimulated with 10-7 M IGF-I (black symbols) or its vehicle (white symbols) for 24 h before determination of the initial rate of Pi uptake in EBSS medium containing 0.05–1.5 mM H3[32P]O4. Data are plotted according to the Lineweaver-Burk method. Each value represents the mean ± SEM of five or six determinations in a representative experiment.

 

View this table:
[in this window]
[in a new window]
 
Table 2. Kinetic analysis of Pi transport stimulation by IGF-I in SaOS-2 cells

 
Time- and dose-dependent stimulation of Glvr-1 mRNA expression by IGF-I in SaOS-2 cells
Northern blotting analysis revealed the presence of a 4-kilobase transcript corresponding to Glvr-1 in SaOS-2 cells. Analysis of time-dependent changes in Glvr-1 mRNA expression in response to 10-7 M IGF-I revealed a transient stimulation that was detectable after 1 h and maximal after 4 h (Fig. 4Go). Glvr-1 mRNA levels then returned to baseline within 18 h. Expression of the housekeeping gene cyclophilin was not significantly affected by IGF-I at any time point (Fig. 4BGo).



View larger version (26K):
[in this window]
[in a new window]
 
Figure 4. Time course of stimulation of Glvr-1 mRNA expression by IGF-I in SaOS-2 cells. A, Ten micrograms of total RNA obtained from confluent SaOS-2 cells stimulated with 10-7 M IGF-I or its vehicle for the indicated times were analyzed by Northern blotting with a probe for human Glvr-1. A representative experiment is shown. The positions of 28S and 18S rRNAs are indicated on the right. B, The membrane was stripped and rehybridized with a probe for cyclophilin. C, The autoradiographies were quantified by densitometry, and the integrated optical density of the Glvr-1 band, corrected for cyclophilin, is shown for each lane below the blots.

 
The induction of Glvr-1 mRNA expression by IGF-I was dose dependent (Fig. 5Go) and, taking into account the lower sensitivity of Northern blot analysis compared with Pi uptake measurements, was approximately parallel to the dose-dependent increase in Pi transport (Fig. 1AGo). An increase in Glvr-1 mRNA was indeed detectable from 10-10 M IGF-I and progressive up to 10-7 M IGF-I. Steady state Glvr-1 mRNA levels in cells exposed to 10-7 M IGF-I for 4 h were consistently more than 4-fold higher than those observed in vehicle-treated cells (Figs. 4CGo and 5CGo).



View larger version (20K):
[in this window]
[in a new window]
 
Figure 5. Dose-dependent effect of IGF-I on Glvr-1 mRNA expression in SaOS-2 cells. A, Ten micrograms of total RNA obtained from confluent SaOS-2 cells stimulated with various concentrations of IGF-I or its vehicle for 4 h were analyzed by Northern blotting with a probe for human Glvr-1. A representative experiment is shown. The positions of 28S and 18S rRNAs are indicated on the right. B, The membrane was stripped and rehybridized with a probe for the 18S rRNA. C, The autoradiographies obtained from three independent experiments were quantified by densitometry. The optical density of the Glvr-1 band was corrected for cyclophilin or 18S rRNA, and the results were expressed as a percentage of the value obtained for 10-7 M IGF-I. Data shown represent the mean ± SEM of the three experiments. *, P < 0.05 compared with vehicle-treated cells.

 
Mechanism of Glvr-1 mRNA induction by IGF-I in SaOS-2 cells
To test whether the observed increase in Glvr-1 mRNA expression was dependent on new RNA synthesis, transcription was inhibited by preincubation of the cells with 1 µg/ml actinomycin D for 1 h before the addition of 10-7 M IGF-I. After 2-h exposure to IGF-I, the cells were harvested, and RNA was analyzed by Northern blotting. Incubation of the cells with actinomycin D, which markedly reduced the abundance of Glvr-1 mRNA in both IGF-I- and vehicle-treated cells, inhibited the induction of Glvr-1 expression by IGF-I, suggesting that this response was dependent on transcription (Fig. 6Go, A and B).



View larger version (18K):
[in this window]
[in a new window]
 
Figure 6. Effect of actinomycin D and cycloheximide on the stimulation of Glvr-1 mRNA expression by IGF-I in SaOS-2 cells. A, Confluent SaOS-2 cells were preincubated with 0.02% DMSO or 1 µg/ml actinomycin D for 1 h before stimulation with 10-7 M IGF-I or its vehicle for 2 h. Total RNA was extracted and analyzed by Northern blotting with a probe for human Glvr-1. A representative experiment is shown. The position of the 28S rRNA is indicated on the right. B, The membrane shown in A was stripped and rehybridized with a probe for the 18S rRNA. C, Confluent SaOS-2 cells were preincubated with 0.05% DMSO or 5 µM cycloheximide for 90 min and stimulated with 10-7 M IGF-I or its vehicle for 4 h. Total RNA was extracted and analyzed by Northern blotting with a probe for human Glvr-1. A representative experiment is shown. The positions of 28S and 18S rRNAs are indicated on the right. D, The membrane shown in C was stripped and rehybridized with a probe for the 18S rRNA.

 
We also examined whether new protein synthesis was required for the stimulation of Glvr-1 expression by IGF-I, using cycloheximide as a translational inhibitor (Fig. 6Go, C and D). SaOS-2 cells were preincubated with 5 µM cycloheximide for 90 min before stimulation with 10-7 M IGF-I for 4 h. The inhibition of protein synthesis did not interfere with the induction of Glvr-1 mRNA by IGF-I. This observation suggests that the synthesis of new intermediary gene products is not necessary to enable SaOS-2 cells to increase Glvr-1 mRNA expression in response to IGF-I.

To investigate whether IGF-I affected the stability of Glvr-1 mRNA, SaOS-2 cells were stimulated for 4 h with 10-7 M IGF-I before transcription was inhibited with actinomycin D (Fig. 7Go). Glvr-1 mRNA levels decreased rapidly after the addition of 1 µg/ml actinomycin D (Fig. 7AGo). The half-life of the Glvr-1 transcript appeared to be shorter than 1 h, and no difference in Glvr-1 mRNA stability could be detected between IGF-I- and vehicle-treated cells (Fig. 7Go, C and D). Together with the results shown in Fig. 6Go, A and B, these observations suggest that the increase in Glvr-1 mRNA steady state levels observed in response to IGF-I in SaOS-2 cells mainly reflects a stimulatory effect of IGF-I on the transcription of this gene.



View larger version (27K):
[in this window]
[in a new window]
 
Figure 7. Effect of IGF-I on the stability of Glvr-1 mRNA in SaOS-2 cells. A, Confluent SaOS-2 cells were stimulated with 10-7 M IGF-I or its vehicle for 4 h before addition of 1 µg/ml actinomycin D for the indicated times. Total RNA was extracted and analyzed by Northern blotting with a probe for human Glvr-1. The positions of 28S and 18S rRNAs are indicated on the right. B, The membrane was stripped and rehybridized with a probe for cyclophilin. C, The autoradiographies were quantified by densitometry. The optical density of the Glvr-1 band in IGF-I-treated (black symbols) and vehicle-treated (white symbols) cells was corrected for cyclophilin and expressed as a percentage of the values obtained at time zero for IGF-I- and vehicle-treated cells, respectively. D, In a second experiment, SaOS-2 cells were stimulated with 10-7 M IGF-I or its vehicle for 4 h before the addition of 2 µg/ml actinomycin D for the indicated times. Total RNA was extracted and analyzed by Northern blotting with probes for Glvr-1 and 18S rRNA. The optical density of the Glvr-1 band in IGF-I-treated (black symbols) and vehicle-treated (white symbols) cells was corrected for 18S rRNA and expressed as a percentage of the values obtained at time zero for IGF-I- and vehicle-treated cells, respectively.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Glvr-1 belongs to a recently identified family of type III NaPi transporters that are expressed in a wide variety of tissues, including kidney, liver, lung, striated muscle, heart, and brain (5). This is to our knowledge the first report on the expression of a type III NaPi transporter in osteoblast-like cells as well as the first description of the molecular identity of a NaPi transporter expressed in bone-forming cells. The size of the Glvr-1 transcript observed in human SaOS-2 cells is similar to that reported for Glvr-1 mRNA in various rat tissues (5).

IGF-I is one of the most abundant growth factors present in bone and has been shown to stimulate bone growth in vivo as well as proliferation and activity of bone-forming cells in vitro (10, 11, 12). In this study, IGF-I significantly enhanced Pi transport and Glvr-1 mRNA expression in SaOS-2 cells. The stimulation of Pi transport was selective, and dose and time dependent. The increase in Pi uptake was related to a change in the Vmax of the transport system and was blocked by transcriptional and translational inhibitors, suggesting that IGF-I may induce the synthesis of new Pi carriers and their insertion into the plasma membrane. IGF-I was previously reported to stimulate Pi transport in two different types of osteogenic cells: rat UMR-106–01 osteoblast-like cells and chicken growth plate chondrocytes (12, 13). Pi transport stimulation by IGF-I in chicken growth plate chondrocytes was comparable in terms of selectivity, and dose and time dependency to that observed in SaOS-2 cells (13). In contrast, higher concentrations of IGF-I were required in UMR-106–01 cells to observe a significant increase in Pi uptake, and the effect was independent of protein synthesis, suggesting a different mechanism of action for IGF-I in UMR-106–01 compared with SaOS-2 cells (12).

IGF-I dose dependently increased Glvr-1 expression in SaOS-2 cells. It appeared to act mainly on the transcription of the Glvr-1 gene without affecting the stability of the Glvr-1 mRNA, and the induction of Glvr-1 mRNA by IGF-I did not require the synthesis of intermediate gene products. The increase in Glvr-1 mRNA expression was transient, and its peak preceded by several hours the maximal expression of Pi transport stimulation. The parallel between the induction of Glvr-1 mRNA expression and Pi transport stimulation strongly suggests that Glvr-1 mediates at least part of the stimulatory effect of IGF-I on Pi transport in SaOS-2 cells. Consistently with this hypothesis the delay observed between the peak of Glvr-1 mRNA expression and the maximal increase in Pi uptake might reflect the time required for the translation of the newly transcribed mRNA and for the insertion of the protein into the plasma membrane to form new functional transport sites.

The apparent Km observed for Pi uptake in SaOS-2 cells (450–500 µM) is on the same order of magnitude as those reported for other osteoblast-like cell lines (3, 17). This apparent Km is higher than those measured for Glvr-1 expressed in oocytes (24 µM) or overexpressed in 208F rat embryo fibroblasts or Mus dunni tail fibroblasts (70 and 53 µM, respectively) (5, 6). These differences could reflect cell type-specific features, such as cell membrane properties, posttranslational modifications, or expression of distinct regulatory proteins; however, the potential existence in SaOS-2 cells of other Pi transport systems in addition to Glvr-1 has not been investigated to date and thus cannot be excluded.

Several in vitro observations suggested that Pi transport plays an important functional role in osteogenic cells and in their matrix vesicles for the initiation of bone matrix calcification (1, 2, 13). The identification of a NaPi transporter expressed in bone-forming cells now provides new molecular tools to study the role of Pi transport and its regulation during bone formation, in particular in relation to bone matrix mineralization. We are currently investigating the expression of Glvr-1 mRNA during the development of murine metatarsals by in situ hybridization. Preliminary data suggest that in this model of endochondral bone formation, Glvr-1 is selectively expressed in a subpopulation of early hypertrophic chondrocytes in a region close to the onset of matrix mineralization (our unpublished data). These observations, which are consistent with a potential role for the Glvr-1 phosphate transporter in initial events of matrix calcification, further suggest important functions for type III NaPi transporters in the context of bone formation in vivo.

In conclusion, this study shows for the first time the expression of a type III NaPi transporter in osteoblast-like cells. Our data also indicate that both the expression of this transporter and Pi transport are stimulated by IGF-I in SaOS-2 cells and thus suggest that type III NaPi transporters may be involved in regulated Pi handling in osteogenic cells. The identification of a NaPi transporter exhibiting regulated expression in bone-forming cells, besides providing new tools to investigate the molecular mechanisms of Pi transport regulation, should also lead to a better understanding of the role of Pi in the metabolism, growth, and differentiation of osteogenic cells as well as in initial steps of bone matrix calcification.


    Acknowledgments
 
We thank Dr. M. P. Kavanaugh for providing us with the human Glvr-1 cDNA. We are indebted to Sabina Campos and Kerstin Schuler for excellent technical help.


    Footnotes
 
1 Part of this work was presented in abstract form at the 18th Annual Meeting of the American Society of Bone and Mineral Research, Seattle, WA, September 7–11, 1996 (22 ). This work was supported by the Swiss National Science Foundation (Grant 32–49839.96). Back

Received May 28, 1997.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Caverzasio J, Montessuit C, Bonjour JP 1996 Functional role of Pi transport in osteogenic cells. News Physiol Sci 11:119–125[Abstract/Free Full Text]
  2. Caverzasio J, Bonjour JP 1996 Characteristics and regulation of Pi transport in osteogenic cells for bone metabolism. Kidney Int 49:975–980[Medline]
  3. Caverzasio J, Selz T, Bonjour JP 1988 Characteristics of phosphate transport in osteoblast-like cells. Calcif Tissue Int 43:83–87[Medline]
  4. Murer H, Biber J 1996 Molecular mechanisms of renal apical Na/phosphate cotransport. Annu Rev Physiol 58:607–618[CrossRef][Medline]
  5. Kavanaugh MP, Miller DG, Zhang W, Law W, Kozak SL, Kabat D, Miller AD 1994 Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc Natl Acad Sci USA 91:7071–7075[Abstract/Free Full Text]
  6. Olah Z, Lehel C, Anderson WB, Eiden MV, Wilson CA 1994 The cellular receptor for gibbon ape leukemia virus is a novel high affinity sodium-dependent phosphate transporter. J Biol Chem 269:25426–25431[Abstract/Free Full Text]
  7. Kavanaugh MP, Kabat D 1996 Identification and characterization of a widely expressed phosphate transporter/retrovirus receptor family. Kidney Int 49:959–963[Medline]
  8. Veldman CM, Markovich D, Schmid C, Murer H 1995 Expression of sodium-dependent phosphate (NadPi) transport in Xenopus laevis oocytes induced by mRNA from 1{alpha},25-dihydroxyvitamin D3-treated rat osteoblast-like cells. Pflugers Arch Eur J Physiol 430:64–67[CrossRef][Medline]
  9. Caverzasio J, Montessuit C, Bonjour JP 1990 Stimulatory effect of insulin-like growth factor-1 on renal Pi transport and plasma 1,25-dihydroxyvitamin D3. Endocrinology 127:453–459[Abstract/Free Full Text]
  10. Schmid C 1993 IGFs: functional and clinical importance. II. The regulation of osteoblast function by hormones and cytokines with special reference to insulin-like growth factors and their binding proteins. J Intern Med 234:535–542[Medline]
  11. Linkhart TA, Subburaman M, Baylink DJ 1996 Growth factors for bone growth and repair: IGF, TGFß and BMP. Bone 19:S1–S12
  12. Campbell PI, Breedlove DK, Kempson SA 1992 Insulin-like growth factor I stimulates sodium-phosphate cotransport in the rat osteoblastic cell line UMR-106–01. Am J Physiol 262:E389–E393
  13. Montessuit C, Bonjour JP, Caverzasio J 1994 Pi transport regulation by chicken growth plate chondrocytes. Am J Physiol 267:E24–E31
  14. Rodan SB, Imai Y, Thiede MA, Wesolowski G, Thompson D, Bar-Shavit Z, Shull S, Mann K, Rodan GA 1987 Characterization of a human osteosarcoma cell line (SaOS-2) with osteoblastic properties. Cancer Res 47:4961–4966[Abstract/Free Full Text]
  15. Fukayama S, Schipani E, Jüppner H, Lanske B, Kronenberg HM, Abou-Samra AB, Bringhurst FR 1994 Role of protein kinase-A in homologous down-regulation of paratyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acid in human osteoblast-like SaOS-2 cells. Endocrinology 134:1851–1858[Abstract/Free Full Text]
  16. Fukayama S, Tashjian AH 1989 Direct modulation by androgens of the response of human bone cells (SaOS-2) to human parathyroid hormone (PTH) and PTH-related protein. Endocrinology 125:1789–1794[Abstract/Free Full Text]
  17. Selz T, Caverzasio J, Bonjour JP 1989 Regulation of Na-dependent Pi transport by parathyroid hormone in osteoblast-like cells. Am J Physiol 256:E93–E100
  18. Burton K 1956 A study of the conditions and mechanisms of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 62:315–323[Medline]
  19. O’Hara B, Johann SV, Klinger HP, Blair DG, Rubinson H, Dunn KJ, Sass P, Vitek SM, Robins T 1990 Characterization of a human gene conferring sensitivity to infection by gibbon ape leukemia virus. Cell Growth Differ 1:119–127[Abstract]
  20. van Zeijl M, Johann SV, Closs E, Cunningham J, Eddy R, Shows TB, O’Hara B 1994 A human amphotropic retrovirus receptor is a second member of the gibbon ape leukemia virus receptor family. Proc Natl Acad Sci USA 91:1168–1172[Abstract/Free Full Text]
  21. Haendler B, Hofer-Warbinek R, Hofer E 1987 Complementary DNA for human T-cell cyclophilin. EMBO J 6:947–950[Medline]
  22. Palmer G, Kavanaugh MP, Bonjour JP, Caverzasio J 1996 Expression of a newly identified phosphate transporter/retrovirus receptor in SaOS-2 osteosarcoma cells and its regulation by insulin-like growth factor-1. J Bone Miner Res [Suppl 1] 11:S123 (Abstract)



This article has been cited by other articles:


Home page
J. Cell Sci.Home page
A. Mukherjee and P. Rotwein
Akt promotes BMP2-mediated osteoblast differentiation and bone development
J. Cell Sci., March 1, 2009; 122(5): 716 - 726.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
A. Mukherjee and P. Rotwein
Insulin-Like Growth Factor-Binding Protein-5 Inhibits Osteoblast Differentiation and Skeletal Growth by Blocking Insulin-Like Growth Factor Actions
Mol. Endocrinol., May 1, 2008; 22(5): 1238 - 1250.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
Y. Yoshiko, G. A. Candeliere, N. Maeda, and J. E. Aubin
Osteoblast Autonomous Pi Regulation via Pit1 Plays a Role in Bone Mineralization
Mol. Cell. Biol., June 15, 2007; 27(12): 4465 - 4474.
[Abstract] [Full Text] [PDF]


Home page
IBMS BoneKEyHome page
J.-P. Bonjour and T. Chevalley
Pubertal Timing, Peak Bone Mass and Fragility Fracture Risk
IBMS BoneKEy, February 1, 2007; 4(2): 30 - 48.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
P. Bottger, S. E. Hede, M. Grunnet, B. Hoyer, D. A. Klaerke, and L. Pedersen
Characterization of transport mechanisms and determinants critical for Na+-dependent Pi symport of the PiT family paralogs human PiT1 and PiT2
Am J Physiol Cell Physiol, December 1, 2006; 291(6): C1377 - C1387.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
C. M. Giachelli, M. Y. Speer, X. Li, R. M. Rajachar, and H. Yang
Regulation of Vascular Calcification: Roles of Phosphate and Osteopontin
Circ. Res., April 15, 2005; 96(7): 717 - 722.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
Y. Yoshiko, N. Maeda, and J. E. Aubin
Stanniocalcin 1 Stimulates Osteoblast Differentiation in Rat Calvaria Cell Cultures
Endocrinology, September 1, 2003; 144(9): 4134 - 4143.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
M. A. Khadeer, Z. Tang, H. S. Tenenhouse, M. V. Eiden, H. Murer, N. Hernando, E. J. Weinman, M. A. Chellaiah, and A. Gupta
Na+-dependent phosphate transporters in the murine osteoclast: cellular distribution and protein interactions
Am J Physiol Cell Physiol, June 1, 2003; 284(6): C1633 - C1644.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
T. Shigematsu, T. Kono, K. Satoh, K. Yokoyama, T. Yoshida, T. Hosoya, and K. Shirai
Phosphate overload accelerates vascular calcium deposition in end-stage renal disease patients
Nephrol. Dial. Transplant., March 1, 2003; 18(90003): iii86 - 89.
[Abstract] [Full Text] [PDF]


Home page
Microbiol. Mol. Biol. Rev.Home page
J. Overbaugh, A. D. Miller, and M. V. Eiden
Receptors and Entry Cofactors for Retroviruses Include Single and Multiple Transmembrane-Spanning Proteins as well as Newly Described Glycophosphatidylinositol-Anchored and Secreted Proteins
Microbiol. Mol. Biol. Rev., September 1, 2001; 65(3): 371 - 389.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
J. Sugai, M. Eiden, M. M. Anderson, N. Van Hoeven, C. D. Meiering, and J. Overbaugh
Identification of Envelope Determinants of Feline Leukemia Virus Subgroup B That Permit Infection and Gene Transfer to Cells Expressing Human Pit1 or Pit2
J. Virol., August 1, 2001; 75(15): 6841 - 6849.
[Abstract] [Full Text]


Home page
Physiol. Rev.Home page
H. Murer, N. Hernando, I. Forster, and J. Biber
Proximal Tubular Phosphate Reabsorption: Molecular Mechanisms
Physiol Rev, October 1, 2000; 80(4): 1373 - 1409.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. Jono, M. D. McKee, C. E. Murry, A. Shioi, Y. Nishizawa, K. Mori, H. Morii, and C. M. Giachelli
Phosphate Regulation of Vascular Smooth Muscle Cell Calcification
Circ. Res., September 29, 2000; 87 (7): e10 - e17.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
G. Palmer, J. Guicheux, J.-P. Bonjour, and J. Caverzasio
Transforming Growth Factor-{beta} Stimulates Inorganic Phosphate Transport and Expression of the Type III Phosphate Transporter Glvr-1 in Chondrogenic ATDC5 Cells
Endocrinology, June 1, 2000; 141(6): 2236 - 2243.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
I. Fernandes, R. Beliveau, G. Friedlander, and C. Silve
NaPO4 cotransport type III (PiT1) expression in human embryonic kidney cells and regulation by PTH
Am J Physiol Renal Physiol, October 1, 1999; 277(4): F543 - F551.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
P. Rodrigues and J. M. Heard
Modulation of Phosphate Uptake and Amphotropic Murine Leukemia Virus Entry by Posttranslational Modifications of PIT-2
J. Virol., May 1, 1999; 73(5): 3789 - 3799.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
Z. Jobbagy, Z. Olah, G. Petrovics, M. V. Eiden, B. D. Leverett, N. M. Dean, and W. B. Anderson
Up-regulation of the Pit-2 Phosphate Transporter/Retrovirus Receptor by Protein Kinase C epsilon
J. Biol. Chem., March 12, 1999; 274(11): 7067 - 7071.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
G. R. Beck Jr., B. Zerler, and E. Moran
Phosphate is a specific signal for induction of osteopontin gene expression
PNAS, July 18, 2000; 97(15): 8352 - 8357.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Palmer, G.
Right arrow Articles by Caverzasio, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palmer, G.
Right arrow Articles by Caverzasio, J.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals